NCT00946179已完成2 期
Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation (Intramuscular Route)
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 130
- 试验地点
- 2
- 主要终点
- To provide information concerning the immunogenicity of intramuscular (IM) Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation.
研究概览
简要总结
This study is in support of the annual application for the variation of the vaccine strains for a marketing authorization.
Objectives:
- To evaluate the compliance, in terms of immunogenicity, of the influenza vaccine (split virion, inactivated) Northern Hemisphere (NH) 2009-2010 formulation in two adult groups, aged 18 to 60 years and aged 61 years or older.
- To describe the safety of the influenza vaccine (split virion, inactivated) NH 2009-2010 formulation in both adult groups.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Aged 18 to 60 years (i.e., to the day before the 61st birthday) or 61 years or older (from the day of the 61st birthday) on the day of inclusion
- •Provision of a signed informed consent
- •Able to attend all scheduled visits and comply with all trial procedures
- •For a woman of child-bearing potential: avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to vaccination, until at least 3 weeks after vaccination
排除标准
- •For a woman of child-bearing potential, known pregnancy or positive urine pregnancy test at Visit 1
- •Febrile illness (temperature ≥ 38 °C) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator judgment
- •Breast-feeding woman
- •Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the trial vaccination
- •Planned participation in another clinical trial during the present trial period
- •Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy
- •Known systemic hypersensitivity to eggs, chicken proteins, neomycin, formaldehyde and octoxynol-9, or to any of the vaccine components, or history of a life-threatening reaction to the trial vaccine or a vaccine containing any of the same substances
- •Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator
- •Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures
- •Receipt of blood or blood-derived products in the past 3 months, that might interfere with the assessment of immune response
- •Receipt of any vaccine in the 4 weeks preceding the trial vaccination
- •Planned receipt of any vaccine in the 3 weeks following the trial vaccination
- •Previous vaccination against influenza in the previous 6 months
- •Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion
- •Known human immunodeficiency virus (HIV), Hepatitis B surface (HBs) antigen or Hepatitis C seropositivity
- •Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent
- •Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or investigator
研究组 & 干预措施
Group 1
Experimental
Participants aged 18 to 60 years at enrollment
干预措施: Influenza virus (split virion, inactivated) vaccine (Biological)
Group 2
Experimental
Participants aged 61 years or older at enrollment
干预措施: Influenza virus (split virion, inactivated) vaccine (Biological)
结局指标
主要结局
To provide information concerning the immunogenicity of intramuscular (IM) Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation.
时间窗: 21 days post-vaccination
To provide information concerning the safety of intramuscular (IM) Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation
时间窗: 0 to 7 days post-vaccination and entire study duration
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route)InfluenzaNCT00945438Sanofi Pasteur, a Sanofi Company131
已完成
4 期
Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong KongInfluenza, HumanNCT03330132The University of Hong Kong1,861
已完成
2 期
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 YearsSwine-origin A/H1N1 InfluenzaInfluenzaNCT00952419Sanofi Pasteur, a Sanofi Company474
已完成
2 期
A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the ElderlySwine-origin A/H1N1 InfluenzaInfluenzaNCT00952276Sanofi548
已完成
1 期
A Phase I Safety and Immunogenicity Study of Mix and Match of Licensed Flu Vaccine and FlumistInfluenzaNCT00231907National Institute of Allergy and Infectious Diseases (NIAID)56